Selecting the Right Radiopharmaceutical CDMO to De-Risk Development, Scale Manufacturing & Support Long- Term Commercial Success
2:00 pm - Wednesday 2nd December 2026
- Evaluating how expertise in isotopes, development and validation, quality assurance, production, supply chain, and regulatory readiness should influence CDMO selection decisions across different stages of TRP development
- Assessing and addressing the operational risks associated with tech transfer and batch reproducibility when partnering with external manufacturing providers
- Determining which strategic considerations including scalability, geographic footprint, and isotope supply integration are most critical for supporting future clinical and commercial growth